Depomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Depomed (DEPO) Tops Q2 EPS by 27c; Boosts FY15 Outlook
July 29, 2015 4:04 PM EDT
NEWARK, Calif., July 29, 2015 /PRNewswire/ --Â Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended June 30, 2015.
"Depomed has rapidly become a leading force in the pain and neurology marketplace, with significant net product revenue growth that positions us to continue to deliver substantial value to our shareholders in both the immediate and long term," said Jim Schoeneck, President and CEO of Depomed. "Growth in the second quarter was led by our flagship product NUCYNTA, which had a strong performance in the first... More
July 29, 2015 4:03 PM EDT
NEWARK, Calif., July 29, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) ("Depomed" or the "Company") today announced that its Board of Directors, after careful consideration and with the assistance of its independent financial and legal advisors, has unanimously rejected the purported revised, highly conditional, unsolicited and non-binding proposal from Horizon Pharma plc (NASDAQ: HZNP) ("Horizon") to acquire all of the outstanding shares of Depomed in an all-stock transaction (the "July 21 Proposal").
The Depomed Board concluded that the July 21 Proposal is inadequate and not in the best interests of... More
July 29, 2015 8:00 AM EDT
NEWARK, Calif., July 29, 2015 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it will release second quarter fiscal year 2015 financial results after the close of market today, Wednesday, July 29, 2015. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
Participants can access the call by dialing 877-317-6789 (United States) or 412-317-6789 (international).... More
